Torley Helen 4

What Happened

• Helen Torley, President & CEO and a director of Halozyme Therapeutics (HALO), exercised 1,923 stock options on July 8, 2026 at $12.07 per share (total cost $23,211) and sold the 1,923 resulting common shares in two open-market transactions the same day.
• Sales details: 888 shares sold at $79.28 for $70,397, and 1,035 shares sold at $80.19 for $82,994, totaling approximately $153,391. These transactions were reported on a Form 4 filed July 9, 2026.

Key Details

• Transaction date: July 8, 2026; Form 4 filed July 9, 2026 (timely).
• Exercise: 1,923 shares exercised at $12.07 (total $23,211).
• Sales: 888 @ $79.28 (≈ $70,397); 1,035 @ $80.19 (≈ $82,994); combined proceeds ≈ $153,391.
• Net cash realized before taxes/fees (approximate): $153,391 − $23,211 = ~$130,180.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Notable footnotes:
  • Sales were made pursuant to a Rule 10b5-1 trading plan adopted March 21, 2025 (F1).
  • The sales prices reported are weighted averages; price ranges and breakdowns are available from the issuer or SEC staff on request (F2, F3).
  • The exercised options were from a grant dated February 22, 2017 with a standard 4‑year vesting schedule; the options have a ten-year term expiring Feb 2027 (F4, F1).

Context

• This was effectively a cashless exercise: options were exercised and the acquired shares were sold the same day. That is a common way for insiders to realize gains from vested options.
• Because the sales were executed under a pre-established 10b5-1 plan, they were preplanned transactions and do not necessarily indicate a change in the CEO’s view of the company.
• For full ownership details or the exact per-share breakdown within the weighted averages, consult the complete Form 4 on EDGAR.